SCHEMBL30906907

SCHEMBL30906907

CC(C)(C)OC(=O)N1CC[C@@H](Nc2ncc(C(F)(F)F)c([Sn](C)(C)C)n2)[C@H](F)C1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 1/20 0.42
▸ CCND1 P24385 1/20 0.42
▸ CCND3 P30281 1/20 0.42
▸ CDK6 Q00534 1/20 0.42
▸ ALK Q9UM73 2/20 0.41
▸ MAPK3 P27361 1/20 0.40
▸ USP30 Q70CQ3 3/20 0.39
▸ SFRP1 Q8N474 2/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ GPR119 Q8TDV5 4/20 0.37
▸ IDH1 O75874 2/20 0.37
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ PREP P48147 1/20 0.37
▸ IDH2 P48735 1/20 0.36
▸ EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30906918 1.00 CDK4 (0.42) CDK4CCND1CCND3CDK6ALK
SCHEMBL30906920 0.92 CDK4 (0.43) CDK4CCND1CCND3CDK6ALK
SCHEMBL27213269 0.88 CCND1 (0.38) CDK4CCND1CCND3CDK6MAPK3
SCHEMBL27213261 0.88 CCND1 (0.38) CDK4CCND1CCND3CDK6MAPK3
SCHEMBL22997722 0.87 CDK4 (0.43) CDK4CCND1CCND3CDK6ALK
SCHEMBL29821030 0.87 CDK4 (0.43) CDK4CCND1CCND3CDK6ALK
SCHEMBL22900954 0.87 CDK4 (0.43) CDK4CCND1CCND3CDK6ALK
SCHEMBL27390146 0.87 CDK4 (0.43) CDK4CCND1CCND3CDK6ALK
SCHEMBL27213273 0.86 IDH1 (0.48) ALKMAPK3USP30SFRP1HDAC4
SCHEMBL22997627 0.81 CDK4 (0.43) CDK4CCND1CCND3CDK6ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150340-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-05-09 — — US disclosed
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150340-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 CDK4 12/4885CCND1 46/4885CCND3 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback